✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic High-Potency CannabisThcPsychosis RiskCannabis PolicyHarm Reduction Why This MattersHigh-THC cannabis products increasingly dominate legal markets,...
Cannabis and Mental Health: Why ‘Cannabis’ and ‘d9-THC’ Are Not the Same Thing
When headlines report that ‘cannabis’ is detrimental for any number of things, the term is almost exclusively used as a proxy for d9-THC.
Cannabis and Mental Health: Why ‘It’s Complicated’ Is Actually the Most Accurate Answer
It is likely more appropriate to view cannabis use as a contributing factor to a condition with a multifactorial etiology (e.g., genetic predisposition, use of other drugs, familial and social factors), or the result of individuals having a shared vulnerability to psychosis and cannabis use.
Adolescent Cannabis Use and Mental Health: Clinical Evidence
Clinical Takeaway Large-scale longitudinal data show that adolescent cannabis use is associated with increased risk of developing psychotic, bipolar, depressive, and anxiety disorders into young adulthood. These are clinically diagnosed conditions, not...
Modern Cannabis Is Hitting Gen Z Mental Health Hard – Neuroscience News
WHY IT MATTERS: Young people who use high-potency cannabis products frequently should understand that their risk for developing or worsening anxiety and depression is meaningfully elevated compared to non-users or infrequent users, and that risk increases the earlier in adolescence use begins. CLINICAL OVERVIEW: The relationship between high-potency cannabis and mental health conditions such as anxiety and depression is not incidental, and the shift toward products with dramatically elevated THC concentrations over recent decades has outpaced what most young developing brains can tolerate without consequence. Gen Z has grown up with near-unrestricted access to concentrates, vape cartridges, and edibles that bear little resemblance to the cannabis of prior generations, making direct comparisons across age cohorts scientifically problematic but still clinically instructive.
420 with CNW — Study Links Psychiatric Disorders to Adolescent Cannabis Use
WHY IT MATTERS: If you are a parent or caregiver of a teenager, this research underscores why adolescent cannabis use should only occur under direct medical supervision with careful psychiatric screening, and why recreational or unsupervised use during brain development carries meaningful risk. CLINICAL OVERVIEW: Research continues to explore the association between adolescent cannabis use and the development of psychiatric disorders, including psychosis, depression, and bipolar spectrum conditions. While these correlational findings are important to acknowledge, clinicians must also consider confounding variables such as pre-existing mental health conditions, adverse childhood experiences, genetic predisposition, and the role of self-medication that may drive early cannabis use in vulnerable youth.
A huge study finds a link between cannabis use in teens and psychosis later – KUOW
WHY IT MATTERS: If you are a parent, caregiver, or young adult considering cannabis use, this research reinforces that delaying use until the brain is more fully developed, generally past age 25, is one of the most important harm reduction strategies available. CLINICAL OVERVIEW: Large-scale longitudinal research continues to reinforce the clinical concern that adolescent cannabis exposure is associated with elevated risk of psychotic disorders and other serious mental health conditions in adulthood. From a neurobiological standpoint, the adolescent brain is undergoing critical endocannabinoid system maturation, and exogenous cannabinoid exposure during this window may disrupt neurodevelopmental trajectories in ways that increase vulnerability to psychosis, particularly in genetically predisposed individuals.
Teens Using Weed Have Doubled Risk For Psychosis, Bipolar Disorder
New research is sounding the alarm on teen cannabis use and mental health risk. Here’s what you need to know: Study tracked teens through age 26 Results showed doubled risk for psychosis and bipolar disorder in teen users ️ The developing brain is uniquely vulnerable to THC exposure ️ This is why cannabis medicine physicians distinguish between adult therapeutic use and adolescent recreational use ️ Age-appropriate care matters As a physician who has treated over 30,000 patients, I firmly believe cannabis has real medical value for adults. But that belief comes with a responsibility to be honest: the teen brain is still under construction, and we need to protect it. Talk to your kids. Talk to your doctor. Get the facts. New research links teen cannabis use to doubled psychosis and bipolar risk by age 26. The developing brain deserves different rules than the adult brain.
Study: Teen Cannabis Use Linked to Double Psychosis Risk – Ground News
New research links adolescent cannabis use to a significantly higher risk of psychosis. Here’s what you need to know: Teen cannabis use was associated with roughly 2x the risk of developing psychotic disorders Genetic predisposition and frequency of use likely play major roles ️ The adolescent brain is still developing well into the mid-20s Medical cannabis programs screen for psychiatric risk factors for exactly this reason This is not about fear — it’s about informed, age-appropriate decisions Cannabis can be powerful medicine for adults under proper guidance. But for teens, the risk-benefit equation is very different. Talk to your kids. Talk to your doctor. Knowledge is harm reduction. New study links teen cannabis use to doubled psychosis risk. This is why age, dose, and clinical oversight matter.
Study: Teen Cannabis Use Linked to Double Psychosis Risk
This is one of the largest studies ever conducted on teen cannabis use and psychiatric outcomes, and it reinforces that age restrictions and youth prevention should be central to any legalization framework. A JAMA Health Forum study of 463,396 adolescents ages 13 to 17 found cannabis use was linked to a twofold increase in psychotic and bipolar disorder risk by age 26. The study represents one of the largest longitudinal investigations of this association, drawing on clinical health records rather than self-reported data.